CDK4/6 inhibitors and SSRIs/SNRIs: A brief review of their safety profiles focusing on potential drug interactions
Dimitra Ioanna Lampropoulou1, Katerina Lioliou1, Eleni Zerva2, Xenia Madia3, Danae Vardoulaki4, GerasimosAravantinos5, Dimitrios Filippou6, Maria Gazouli71 ECONCARE, Health Research & Consulting, 11528, Athens, Greece.2 Centre Interdisciplinaire de Nanoscience de Marseille, Aix-Marseille University, CNRS, UMR 7325 CINaM 163, Marseille, France.3 NOVARTIS Hellas, Athinon – Lamias National Rd (12th km) 14451, Metamorfosi Greece.4 Department of Medical Oncology, …